Alzheimer's disease severity, objectively determined and measured
Abstract
With expansion of clinical trials to individuals across the spectrum of Alzheimer disease (AD) from preclinical to symptomatic phases, it is increasingly important to quantify AD severity using methods that capture underlying pathophysiology.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jan 01, 2016
- Source ID
- 10.1016/j.dadm.2016.08.005
Entities
People
- Alden L. Gross
- Dan M. Mungas
- Jeannie‐marie S. Leoutsakos
- Marilyn S. Albert
- Richard N Jones
- The Alzheimer’s Disease Neuroimaging Initiative*
Organizations
- AbbVie
- Alpert Medical School
- BioClinica
- Biogen
- Brown University
- Canadian Institutes of Health Research
- Chiron Corporation
- Eli Lilly and Company
- Foundation for the National Institutes of Health
- GE HealthCare
- Government of Canada
- Johns Hopkins Bloomberg School of Public Health
- Johns Hopkins School of Medicine
- Johns Hopkins University
- Laboratoires Servier
- Lundbeck
- McGill University
- Merck & Co.
- National Institute of Biomedical Imaging and Bioengineering
- National Institute on Aging
- National Institutes of Health
- Norman Cousins Center for Psychoneuroimmunology
- Pfizer
- Pfizer (Canada)
- Roche (United States)
- Takeda Pharmaceutical Company
- United States Department of Defense
- University of California, San Diego